Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis

Association of Anti-Cyclic Citrullinated Peptide Antibody in a Sample of Adult Patients With Psoriasis and Psoriatic Arthropathy

“…This study also showed that PsA patients in comparison to patients with psoriasis have a positive ACPA with a statistically significant difference (p=0.023), which was agreed with a study done by Abdel Fattah et al (p<0.001) and Candia et al (p=0.01) [13,14]. On the other hand, other studies like Shibata [19]. This contradiction may be due to the small size of PsA (n=16) and psoriasis (n=15) patients used in their study.…”

“…This is in agreement with previous studies such as Abdel Fattah et al, Candia et al, Inanc et al, Bogliolo et al, and Cruyssen et al [13][14][15][16][17]. Did not find a significant difference between healthy persons and patients with PsA regarding the positivity for ACPA [18,19]. This contradiction may have been due to the small patients and control sizes used in their studies.…”

Up-regulation of CD64-expressing monocytes with impaired FcγR function reflects disease activity in polyarticular psoriatic arthritis

“…Thus, secondary germinal centres in the PsA synovium (5), as well as increased concentrations of circulating immune complexes (ICs), immunoglobulin (Ig)A, and IgG (6) have been described. Autoantibodies including low titres of rheumatoid factor (RF) have also been detected (7)(8)(9)(10), especially in polyarthritic PsA (11). The autoantibodies can exacerbate systemic and local inflammation by interacting with monocytes/macrophages expressing FcRs for IgG (FcγRs) and IgA (FcαR; CD89).…”

IL-12 Family Cytokines in Inflammation and Bone Erosion of Rheumatoid Arthritis

“…As such, IL-15 blockade abolishes severe joint inflammation in collagen induced-arthritis mouse models (Ruchatz et al, 1998). In the CD4 + T-cell population, Th17 has been demonstrated as a pathogenic T-cell that produces IL-17 to induce neutrophil migration (Shibata et al, 2009). IL-17 is known to stimulate receptor-activator of nuclear factor kappa-B ligand (RANKL) production by osteoblast cells to promote osteoclastogenesis in RA bone erosion (Joosten et al, 2003).…”